Background: Previous studies on Deva-5 traditional prescription, which has long been used in traditional medicine for the treatment of influenza, have demonstrated inhibitory activity against influenza A (H3) virus and antimicrobial activity against Staphylococcus aureus. Based on this traditional formula, De-Mon syrup was developed through pharmaceutical processing. Experimental studies have shown that this syrup possesses anti-inflammatory properties. Therefore, conducting a clinical study to evaluate its therapeutic effect in influenza is warranted. Aim: To investigate the anti-inflammatory effect of De-Mon syrup, derived from a traditional herbal formulation, in patients with influenza. Materials and Methods: A randomized controlled clinical trial with a parallel design was conducted among 160 patients diagnosed with influenza (ICD-10: J09–J11) who met the inclusion criteria. Participants were randomly assigned into two groups. The treatment group received standard influenza therapy with oseltamivir combined with De-Mon syrup, administered four times daily for five days at age-appropriate doses for children and adults. The control group received oseltamivir twice daily for five days. Complete blood count parameters were measured before and after treatment, and the results were statistically analyzed. Result: According to the study results, the adult treatment group demonstrated a statistically significant reduction in white blood cell and neutrophil counts compared with the control group (p<0.05). Similarly, when children in the treatment group were compared with those in the control group, white blood cell count, C-reactive protein levels, and neutrophil counts were significantly decreased, indicating statistically significant differences (p<0.05). Conclusion De-mon syrup, based on a traditional prescription, significantly reduced white blood cell count, C-reactive protein, and neutrophil levels in patients with influenza (p<0.05), indicating a potential anti-inflammatory effect.

Background: Pulmonary alveolar proteinosis (PAP) is a rare lung disorder characterized by the accumulation of surfactant within the alveoli, leading to impaired gas exchange and respiratory insufficiency. Although the disease is uncommon, it significantly affects patients’ quality of life and requires specific diagnostic and therapeutic approaches. Whole lung lavage (WLL) is considered the standard treatment; however, it has not been widely implemented in Mongolia. We report the first successful case of WLL performed for PAP in Mongolia. Case Presentation: A 56-year-old male presented with dyspnea. Chest computed tomography demonstrated a bilateral “crazy paving” pattern. Bronchoalveolar lavage fluid was positive for periodic acid–Schiff (PAS) staining, and anti–GM-CSF antibodies were detected, confirming the diagnosis of PAP. WLL was performed under general anesthesia using a double-lumen endotracheal tube with bronchoscopic guidance. One lung was ventilated with 100% oxygen while the contralateral lung was sequentially lavaged with 800–1000 mL of warm (37°C) saline per cycle until the effluent became clear. A total of approximately 20 liters of saline was used. Result: The procedure was completed successfully without complications. Following treatment, the patient showed marked clinical improvement with reduced dyspnea and increased exercise tolerance. Oxygen saturation improved from 88% to 93%, and spirometric parameters (FVC, FEV₁) demonstrated improvement. Chest imaging revealed a reduction in pulmonary opacities. Conclusion This case demonstrates the successful implementation of whole lung lavage (WLL) in Mongolia and highlights its importance in improving the diagnostic and therapeutic capacity for rare pulmonary diseases such as pulmonary alveolar proteinosis. The procedure resulted in significant improvement in clinical, functional, and radiological parameters, consistent with findings from international studies. Early diagnosis of PAP and the adoption of standardized protocols in accordance with international guidelines are essential to optimize treatment outcomes and enhance patients’ quality of life.